The read at a glance
Computed from the FY2025 annual filing. Full history and the components behind each score are in the app.
- Distress risk · Altman Z-Score 3.02 — safe zoneOK
- Earnings-manipulation signal · Beneish M -2.56 — no flag raisedOK
- Earnings quality 84/100 — accruals in line with cashOK
Where the revenue comes from
Fiscal 2025, as HALOZYME THERAPEUTICS, INC. reports it. History and quarterly detail are in the app.
- Royalties$867.8M
- Product sales, net$376.4M
- Revenues under collaborative agreements$152.3M
Leadership changes
From HALOZYME THERAPEUTICS, INC.'s own filings, the day they're filed.
- Darren Snellgrove · Chief Financial Officer · appointmenteff. 2026-06-08
- David Ramsay · CFO · appointmenteff. 2026-06-08
- David Ramsay · Chief Financial Officer · appointmenteff. 2026-03-23
Latest filings
- 10-Q · Quarterly report2026-05-11
- 8-K · Company announcement2026-05-11
- 8-K · Company announcement2026-05-07
- 8-K · Company announcement2026-04-30
- 8-K · Company announcement2026-04-24
In the full recordFree for 14 days
- The filings, readable — with what changed vs the prior year highlighted🔒
- Full financial statements, industry-aware, every figure source-linked🔒
- Forensic score history & components — the trend, not one year🔒
- Ownership: insider buys/sells, clusters, activist stakes🔒
- Ana — ask anything about HALOZYME THERAPEUTICS, INC., every answer cited🔒
- The Intelligence Brief — added when HALOZYME THERAPEUTICS, INC.'s brief passes our SEC-figure check🔒
Every figure links to the filing it came from, and analysis whose figures don't match SEC data is rejected before publication.
14-day free trial, no credit card. For research purposes only; not investment advice.